BR Biopharma, Inc. (NASDAQ:BRBI) Sees Large Drop in Short Interest

BR Biopharma, Inc. (NASDAQ:BRBI) was the target of a significant drop in short interest in April. As of April 30th, there was short interest totaling 942 shares, a drop of 96.4% from the April 15th total of 26,338 shares. Based on an average daily trading volume, of 3,916 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.0% of the shares of the stock are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings began coverage on shares of BR Biopharma in a research report on Friday, February 13th. They issued a “sell (e-)” rating on the stock. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

BR Biopharma Stock Performance

Shares of NASDAQ BRBI traded down $0.20 during trading on Wednesday, hitting $13.83. The company had a trading volume of 469 shares, compared to its average volume of 4,471. BR Biopharma has a 52 week low of $12.15 and a 52 week high of $67.01. The firm has a 50-day moving average of $14.82.

BR Biopharma (NASDAQ:BRBI) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.09 earnings per share for the quarter. The company had revenue of $25.95 million for the quarter.

BR Biopharma Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Tuesday, May 19th will be issued a dividend of $0.147 per share. This represents a $0.59 annualized dividend and a yield of 4.2%. The ex-dividend date is Tuesday, May 19th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BR Biopharma stock. Acuitas Investments LLC bought a new position in BR Biopharma, Inc. (NASDAQ:BRBI) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 3,000 shares of the company’s stock, valued at approximately $45,000. BR Biopharma makes up about 3.2% of Acuitas Investments LLC’s portfolio, making the stock its 7th largest holding.

About BR Biopharma

BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.